Chemistry:Deruxtecan: Difference between revisions
From HandWiki
(update) |
(No difference)
|
Latest revision as of 15:56, 11 August 2025
Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor.[1]
It is available linked to specific monoclonal antibody (antibody–drug conjugate), such as:
- Trastuzumab deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma.[2]
- Patritumab deruxtecan, an experimental antibody–drug conjugate to treat non-small-cell lung cancer.[3][4][5]
- Ifinatamab deruxtecan, an experimental anti-cancer treatment.[6][7]
- Datopotamab deruxtecan (Datroway), used for the treatment of breast cancer
References
- ↑ "A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model". https://mct.aacrjournals.org/content/molcanther/17/7/1494.full.pdf.
- ↑ "FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies". U.S.Food and Drug Administration (FDA) (Press release). 20 December 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
This article incorporates text from this source, which is in the public domain.
- ↑ Yu, H.A.; Baik, C.S.; Gold, K.; Hayashi, H.; Johnson, M.; Koczywas, M.; Murakami, H.; Nishio, M. et al. (September 2020). "LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC". Annals of Oncology 31: S1189–S1190. doi:10.1016/j.annonc.2020.08.2295.
- ↑ Krop, Ian E.; Masuda, Norikazu; Mukohara, Toru; Takahashi, Shunji; Nakayama, Takahiro; Inoue, Kenichi; Iwata, Hiroji; Toyama, Tatsuya et al. (1 June 2022). "Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).". Journal of Clinical Oncology 40 (16_suppl): 1002. doi:10.1200/JCO.2022.40.16_suppl.1002.
- ↑ Jänne, Pasi A.; Baik, Christina; Su, Wu-Chou; Johnson, Melissa L.; Hayashi, Hidetoshi; Nishio, Makoto; Kim, Dong-Wan; Koczywas, Marianna et al. (1 January 2022). "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer". Cancer Discovery 12 (1): 74–89. doi:10.1158/2159-8290.CD-21-0715. PMID 34548309.
- ↑ Katsumata, Len; Deguchi, Tsuneo; Hasegawa, Jun; Yamato, Michiko; Nishiya, Yumi; Watanabe, Akiko; Honda, Tomoyo; Minami, Megumi et al. (4 April 2023). "Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization". Cancer Research 83 (7_Supplement): 4891. doi:10.1158/1538-7445.AM2023-4891.
- ↑ Patel, M.R.; Doi, T.; Koyama, T.; Falchook, G.S.; Friedman, C.F.; Piha-Paul, S.A.; Gutierrez, M.; Awad, M.M. et al. (October 2023). "690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study". Annals of Oncology 34: S481–S482. doi:10.1016/j.annonc.2023.09.1876.
 |  |
